Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib + bevacizumab + pemetrexed first-line for EGFR-mutant lung adenocarcinoma with brain metastases
ChiCTR2000035591Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of almonertinib, bevacizumab and pemetrexed in Non-small cell lung cancer adenocarcinoma (NSCLC) and brain metastases, sponsored by Shandong Cancer Hospital. Primary endpoints: progression-free survival and intracranial progression-free survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
almonertinibbevacizumabpemetrexed
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2000035591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035591.